These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24673736)

  • 1. National Working Group Meeting on ALK diagnostics in lung cancer.
    Cooper W; Fox S; O'Toole S; Morey A; Frances G; Pavlakis N; O'Byrne K; Dettrick A; Leong T; Rathi V; Spagnolo D; Hemmings C; Singh M; Moffat D; Tsao MS; Wilner K; Buller R; Pitman Lowenthal S; Arifeen S; Binko J; Alam M
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl 2():11-7. PubMed ID: 24673736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
    Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
    Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
    Leighl NB; Rekhtman N; Biermann WA; Huang J; Mino-Kenudson M; Ramalingam SS; West H; Whitlock S; Somerfield MR
    J Clin Oncol; 2014 Nov; 32(32):3673-9. PubMed ID: 25311215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
    V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
    Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.
    Marchetti A; Ardizzoni A; Papotti M; Crinò L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C
    J Thorac Oncol; 2013 Mar; 8(3):352-8. PubMed ID: 23407559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
    Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR
    J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.
    Krawczyk P; Chorostowska-Wynimko J; Dziadziuszko R; Jassem J; Krzakowski M; Langfort R; Puacz E; Wasąg B; Wojas-Krawczyk K
    Pneumonol Alergol Pol; 2014; 82(5):437-44. PubMed ID: 25133812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.
    Black RC; Khurshid H
    R I Med J (2013); 2015 Oct; 98(10):25-8. PubMed ID: 26422542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)].
    von Laffert M; Schirmacher P; Warth A; Weichert W; Büttner R; Huber RM; Wolf J; Griesinger F; Dietel M; Grohé Ch
    Pneumologie; 2016 Apr; 70(4):277-81. PubMed ID: 26984109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas.
    Li Z; Dacic S; Pantanowitz L; Khalbuss WE; Nikiforova MN; Monaco SE
    Am J Clin Pathol; 2014 Mar; 141(3):420-8. PubMed ID: 24515771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement.
    Fujiwara A; Higashiyama M; Kanou T; Tokunaga T; Okami J; Kodama K; Nishino K; Tomita Y; Okamoto I
    Lung Cancer; 2014 Feb; 83(2):302-4. PubMed ID: 24360322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostics of non-small cell lung carcinoma].
    Salmenkivi K; Knuuttila A
    Duodecim; 2014; 130(7):701-4. PubMed ID: 24772787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.
    DiStasio M; Chen Y; Rangachari D; Costa DB; Heher YK; VanderLaan PA
    Clin Lung Cancer; 2017 Sep; 18(5):e349-e356. PubMed ID: 28377205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.